Related Experiment Video
Updated: Oct 4, 2025

Development of an Economical DNA Delivery System by "Acufection" and its Application to Skin Research
Published on: April 19, 2017
Experience of a Single Academic Center Using IL-1 Inhibition for Rare Dermatologic Conditions
Evidence-based literature regarding management of rare and severe dermatologic disease is limited. Canakinumab and anakinra, two therapeutics used for inhibiting IL-1 pathways, have seen increased utilization for treatment of refractory dermatoses. We sought to better characterize the breadth of dermatologic conditions for which these medications could be utilized.
Evidence-based literature regarding management of rare and severe dermatologic disease is limited. Canakinumab and anakinra, two therapeutics used for inhibiting IL-1 pathways, have seen increased utilization for treatment of refractory dermatoses. We sought to better characterize the breadth of dermatologic conditions for which these medications could be utilized.

